<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995302</url>
  </required_header>
  <id_info>
    <org_study_id>MicroneedlingScar</org_study_id>
    <nct_id>NCT04995302</nct_id>
  </id_info>
  <brief_title>Microneedling Therapy With or Without Amnion Bilayer Sheeting on Scar Tissue</brief_title>
  <official_title>The Comparison of Microneedling Therapy With or Without Amnion Bilayer Sheeting on Post-Burn Hypertrophic Scar Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr.dr.Irma Bernadette, SpKK (K)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the outcome of microneedling therapy with or without&#xD;
      amnion bilayer sheeting on post-burn hypertrophic scar tissue. A clinical trial will be&#xD;
      conducted with 17 samples, from September to December 2021.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High degree burn injuries commonly result in abnormal scar formation, and therapy for this&#xD;
      hypertrophic scar remains a challenge. For years, microoneedling has been used for treating&#xD;
      hypertrophic scars, and an addition of amnion bilayer sheeting is expected to provide a more&#xD;
      favorable outcome. This study aims to compare microneedling therapy with or without amnion&#xD;
      bilayer sheeting on post-burn hypertrophic scars tissue. This is an interventional study with&#xD;
      17 samples, aged 18-50 years old. Therapeutic outcomes will be evaluated using visual analog&#xD;
      scale, degree of erythema, patient's subjective evaluation, dermoscope, biopsy, and skin&#xD;
      ultrasound.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In this study, one scar in one subject, will be divided into two areas, one-half of the scar will receive an intervention of microneedling, and the other half will receive microneedling+amnion bilayer. Hence, one subject will receive both interventions at the same time</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Subjective Pain in one month</measure>
    <time_frame>Baseline, day 7, day 30</time_frame>
    <description>Using Visual Analog Scale (0-10, 0 indicates no pain and 10 indicates severe pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Erythema Degree in one month</measure>
    <time_frame>Baseline, day 7, day 30</time_frame>
    <description>Using Erythema score (0-4, 0 indicates no erythema and 4 indicates severe erythema)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Dermoscopy Evaluation in one month</measure>
    <time_frame>Baseline, day 7 , day 30</time_frame>
    <description>Qualitative description of blood vessel structure, pigmentation density and erythema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Biopsy Evaluation in one month</measure>
    <time_frame>Baseline, Day 7 and day 30</time_frame>
    <description>Descriptive evaluation using HE staining</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Skin Thickness in one month</measure>
    <time_frame>Baseline, Day 7 and day 30</time_frame>
    <description>Evaluation with USG of epidermal and dermal layer (in pixels)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Subjective Improvement in one month</measure>
    <time_frame>Baseline , Day 7 and day 30</time_frame>
    <description>Using Patient and Observer Scar Assessment Scale (Patients scored from 1-10 in pain, itch, color, stiffness, thickness and irregularity of their scar, observer gives score on vascularity, pigmentation, thickness, relief, pliability, and surface area)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Subjective Improvement in one month</measure>
    <time_frame>Baseline , Day 7 and day 30</time_frame>
    <description>Using Modified Vancouver Scar Scale (Evaluating pigmentation (score 0-3), vascularity (0-3), pliability (0-5), height (0-5))</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Scars, Hypertrophic</condition>
  <condition>Burn Scar</condition>
  <arm_group>
    <arm_group_label>Microneedling and Amnion Bilayer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Microneedling is a dermaroller procedure that uses small needles to prick the skin. Amnion bilayer is used as an additional therapy after microneedling therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microneedling</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microneedling is a dermaroller procedure that uses small needles to prick the skin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microoneedling and Amnion Bilayer</intervention_name>
    <description>Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with amnion bilayer for 72 hours.</description>
    <arm_group_label>Microneedling and Amnion Bilayer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microoneedling</intervention_name>
    <description>Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with an antibacterial gauze dressing.</description>
    <arm_group_label>Microneedling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, aged 18-50 years old&#xD;
&#xD;
          -  Patients with post-burn, mature hypertrophic scars, localized in any areas other than&#xD;
             the face, with a minimum of 5 cm in diameter.&#xD;
&#xD;
          -  Patients are willing to participate in the study and sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with scars less than 5 cm in diameter&#xD;
&#xD;
          -  Patients with scars localized solely in the face&#xD;
&#xD;
          -  Hypertrophic scars with keloid&#xD;
&#xD;
          -  Patients with comorbidities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irma B Sitohang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fakultas Kedokteran Universitas Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irma B Sitohang</last_name>
    <phone>+62818130761</phone>
    <email>irma_bernadette@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>dr. Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>Jakarta Pusat</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Irma B Sitohang, MD, Ph.D</last_name>
      <phone>+62818130761</phone>
      <email>irma_bernadette@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 31, 2021</last_update_submitted>
  <last_update_submitted_qc>July 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Dr.dr.Irma Bernadette, SpKK (K)</investigator_full_name>
    <investigator_title>Irma Bernadette S. Sitohang, MD, PhD - Head of Cosmetic Dermatology Division, Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia</investigator_title>
  </responsible_party>
  <keyword>Microneedling</keyword>
  <keyword>Amnion bilayer</keyword>
  <keyword>Scar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cicatrix, Hypertrophic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

